Significant sex differences exist in the genomic aberrations underlying disease pathology, including a higher prevalence of SF3B1, SRSF2, and ASXL1 mutations in males and DNMT3A mutations in females with clonal hematopoiesis indeterminate potential and myelodysplastic syndromes (MDS) [8]. Here, ASXL1 is linked to myelodysplastic syndrome.